Mst Continus (Morphine Sulfate)

Morphine sulfate, the active ingredient in Mst Continus, is an opioid analgesic presented as an oral formulation for oral use. It is employed to manage moderate to severe pain, including postoperative, cancer‑related and chronic pain, in adult patients when other analgesics are insufficient.

GNH USA supplies Mst Continus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU quality standards and is distributed under strict regulatory oversight. Our global logistics network ensures timely delivery to authorized healthcare providers.

Morphine sulfate is an opioid analgesic used in the management of pain across several clinical contexts. - Postoperative pain: provides effective relief after surgical procedures. - Cancer pain: reduces severe pain associated with malignant disease. - Chronic severe pain: controls persistent pain unresponsive to non‑opioid therapies.

Morphine sulfate may cause a range of adverse reactions, varying from mild to potentially life‑threatening.

Common Side Effects: - Nausea: feeling of sickness and urge to vomit. - Constipation: reduced bowel movements and hard stools. - Drowsiness: increased sleepiness or fatigue. - Dizziness: sensation of light‑headedness or unsteadiness. - Dry mouth: reduced salivation causing throat discomfort. - Vomiting: expulsion of stomach contents.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing that can be fatal. - Severe hypotension: marked drop in blood pressure leading to fainting. - Anaphylaxis: sudden, severe allergic reaction with rash, swelling, and airway compromise. - Adrenal insufficiency: impaired cortisol production causing weakness and electrolyte imbalance. - Seizures: uncontrolled electrical activity in the brain.

When prescribing morphine sulfate, clinicians should observe several safety precautions to minimize risks. - Assess opioid tolerance: evaluate patient’s prior exposure to opioids before initiating therapy. - Monitor respiratory function: watch for signs of respiratory depression, especially during dose titration. - Avoid concurrent CNS depressants: limit use with benzodiazepines, barbiturates, or alcohol. - Adjust for organ impairment: modify dosing in patients with significant hepatic or renal dysfunction. - Educate on dependence risk: inform patients about the potential for addiction and proper disposal of unused medication. - Store at ambient temperature: keep in original packaging, protect from moisture and heat.

Morphine sulfate can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Benzodiazepines: combined use may cause profound respiratory depression. - MAO inhibitors: concurrent use can precipitate severe hypertension or serotonin syndrome. - Other opioids: additive effects increase risk of respiratory depression and sedation.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin): may raise morphine plasma levels. - CYP3A4 inducers (e.g., rifampin): may reduce morphine effectiveness. - Serotonergic agents (e.g., SSRIs): increase risk of serotonin syndrome.